Next 10 |
2024-07-28 05:40:15 ET Summary Quest Diagnostics reported Q2 earnings beat on EPS and revenue, with 9.5% year-over-year revenue growth. Company's acquisitions and focus on expanding clinical services are key growth drivers. Despite strong earnings, risks include economic downt...
BD, Quest Diagnostics Join Forces to Develop Companion Diagnostics for Cancer, Other Diseases PR Newswire Collaboration on Flow Cytometry-Based Companion Diagnostics to Advance Personalized Health Care FRANKLIN LAKES, N.J. and SECAUCUS, N.J. , July 25, 20...
2024-07-24 07:00:10 ET Eric Coldwell from Robert W. Baird issued a price target of $154.00 for DGX on 2024-07-24 06:36:00. The adjusted price target was set to $154.00. At the time of the announcement, DGX was trading at $140.96. The overall price target consensus is at ...
2024-07-23 12:12:08 ET Quest Diagnostics Incorporated (DGX) Q2 2024 Earnings Conference Call July 23, 2024 08:30 a.m. ET Company Participants Jim Davis - Chairman, Chief Executive Officer, President Sam Samad - Chief Financial Officer Shawn Bevec - Vice President...
2024-07-23 06:48:29 ET More on Quest Diagnostics Quest Diagnostics: On A Quest For Growth Quest Diagnostics: Let's Keep Waiting Labcorp, Quest among health firms to cite impact from CrowdStrike issue Seeking Alpha’s Quant Rating on Quest Diagnostics ...
Quest Diagnostics Reports Second Quarter 2024 Financial Results; Raises Guidance for Full Year 2024 PR Newswire Second quarter revenues of $2.40 billion , up 2.5% from 2023 Second quarter reported diluted earnings per share ("EPS") of $2.03 , down 1.0% from 2023; a...
2024-07-19 12:49:34 ET More on Quest Diagnostics, Labcorp, etc. Quest Diagnostics: On A Quest For Growth Laboratory Corporation: Limited Upside Visibility, Reiterate Hold Quest Diagnostics: Let's Keep Waiting Lisata to use Haystack technology to evaluate panc...
2024-07-18 11:27:06 ET More on Quest Diagnostics, Lisata Quest Diagnostics: On A Quest For Growth Lisata Therapeutics, Inc. (LSTA) Q1 2024 Earnings Call Transcript Lisata Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation Citi upgrades Illumina...
2024-07-18 10:55:00 ET Summary Global stock markets were mixed in the second quarter, with U.S. Large Cap growth stocks continuing to march to their own beat, U.S. Small Cap stocks declining, and International stocks treading water. Speculation is widespread with growth continuing...
BALTIMORE, Md. and BASKING RIDGE, N.J., July 18, 2024 (GLOBE NEWSWIRE) -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, and Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors an...
News, Short Squeeze, Breakout and More Instantly...
Quest Diagnostics Incorporated Company Name:
DGX Stock Symbol:
NYSE Market:
Quest Diagnostics Incorporated Website:
BD, Quest Diagnostics Join Forces to Develop Companion Diagnostics for Cancer, Other Diseases PR Newswire Collaboration on Flow Cytometry-Based Companion Diagnostics to Advance Personalized Health Care FRANKLIN LAKES, N.J. and SECAUCUS, N.J. , July 25, 20...
2024-07-24 07:00:10 ET Eric Coldwell from Robert W. Baird issued a price target of $154.00 for DGX on 2024-07-24 06:36:00. The adjusted price target was set to $154.00. At the time of the announcement, DGX was trading at $140.96. The overall price target consensus is at ...
Quest Diagnostics Reports Second Quarter 2024 Financial Results; Raises Guidance for Full Year 2024 PR Newswire Second quarter revenues of $2.40 billion , up 2.5% from 2023 Second quarter reported diluted earnings per share ("EPS") of $2.03 , down 1.0% from 2023; a...